Ni
Nichi-Iko
Toyama JPFounded 19653,000 employees
Private CappharmaPrivateOncology
Platform: Generic JP
Market Cap
N/A
All Drugs
4
Clinical Trials
4
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| NIC-5654 | NIC-5654 | Phase 1/2 | 1 | SOS1 | MDDDMD | ||
| Niraglumide | NIC-7919 | Phase 2 | 1 | WEE1 | GA | ||
| Zanuratamab | NIC-6449 | Phase 1 | 1 | TIM-3 | TTR AmyloidosisFSGS | ||
| Daramavacamten | NIC-5418 | Preclinical | 1 | CFTR | Wet AMDDravet |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (4)